Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension

[1]  R. Roskoski.  Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. , 2019, Pharmacological research.

[2]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[3]  A. Giordano,et al.  CDK9 inhibitors in acute myeloid leukemia , 2018, Journal of experimental & clinical cancer research : CR.

[4]  G. Viale,et al.  Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. , 2018, The Lancet. Oncology.

[5]  W. Xie,et al.  Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats , 2018, BioMed research international.

[6]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[7]  Yan Zhou,et al.  miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. , 2017, Cancer research.

[8]  T. Bachelot,et al.  Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis , 2017, Breast Cancer.

[9]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[10]  S. Loi,et al.  Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). , 2016, The oncologist.

[11]  Lili Ji,et al.  Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NFκB, Egr1, Nrf2, MAPKs and PI3K signals. , 2016, Environmental toxicology and pharmacology.

[12]  M. Dobelbower,et al.  Correction: Kinomic Profiling of Electromagnetic Navigational Bronchoscopy Specimens: A New Approach for Personalized Medicine , 2016, PloS one.

[13]  Ping Chen,et al.  Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.

[14]  W. Seeger,et al.  Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension , 2016, European Respiratory Journal.

[15]  Shunqiang Li,et al.  Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer , 2016, Oncotarget.

[16]  Zhenghu Chen,et al.  Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity , 2016, Scientific Reports.

[17]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[18]  J. Ettl.  Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer , 2016, Breast Care.

[19]  R. Roskoski.  Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. , 2016, Pharmacological research.

[20]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[21]  B. Jessen,et al.  Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies , 2015, Clinical Cancer Research.

[22]  Rosanne Raso,et al.  Changing a paradigm. , 2015, Nursing management.

[23]  G. Naik,et al.  High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes , 2015, PloS one.

[24]  L. Gelbert,et al.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. , 2015, Bioorganic & Medicinal Chemistry Letters.

[25]  Jia Zhou,et al.  miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma , 2015, Molecular Cancer Research.

[26]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[27]  Jeffrey A Jones,et al.  Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia , 2015, Leukemia.

[28]  Marion Peyressatre,et al.  Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors , 2015, Cancers.

[29]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[30]  G. Shapiro,et al.  Targeting CDK 4 and CDK 6 : From Discovery to Therapy , 2015 .

[31]  M. Dobelbower,et al.  Kinomic Profiling of Electromagnetic Navigational Bronchoscopy Specimens: A New Approach for Personalized Medicine , 2014, PloS one.

[32]  M. Capecchi,et al.  Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension , 2014, Nature Medicine.

[33]  B. Clotet,et al.  Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile &agr; motif and HD domain-containing protein-1 (SAMHD1) activity , 2014, AIDS.

[34]  C. Criscitiello,et al.  Dinaciclib for the treatment of breast cancer , 2014, Expert opinion on investigational drugs.

[35]  Nicholas W Morrell,et al.  Relevant issues in the pathology and pathobiology of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[36]  S. Grant,et al.  Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism , 2013, Molecular Cancer Therapeutics.

[37]  M. Humbert,et al.  Pathogenesis of pulmonary arterial hypertension: lessons from cancer , 2013, European Respiratory Review.

[38]  M. Humbert,et al.  Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword? , 2013, Seminars in Respiratory and Critical Care Medicine.

[39]  S. Olesen,et al.  Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. , 2013, ACS chemical biology.

[40]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[41]  H. Ghofrani,et al.  Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.

[42]  B. Dahal,et al.  Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. , 2012, American journal of respiratory and critical care medicine.

[43]  L. Farkas,et al.  The monocrotaline model of pulmonary hypertension in perspective. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[44]  Philip Griebel,et al.  Peptide arrays for kinome analysis: New opportunities and remaining challenges , 2011, Proteomics.

[45]  Phillip A. Schwartz,et al.  Protein kinase biochemistry and drug discovery. , 2011, Bioorganic chemistry.

[46]  H. Ghofrani,et al.  Mechanisms of disease: pulmonary arterial hypertension , 2011, Nature Reviews Cardiology.

[47]  A. Mazo,et al.  p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors , 2011, Oncogene.

[48]  S. Sakao,et al.  Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. , 2011, International journal of cardiology.

[49]  H. Ghofrani,et al.  Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. , 2010, American journal of respiratory and critical care medicine.

[50]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[51]  Henk M. W. Verheul,et al.  Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods , 2010, Analytical and bioanalytical chemistry.

[52]  E. Lees,et al.  Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. , 2010, ACS medicinal chemistry letters.

[53]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[54]  Anindya Dutta,et al.  p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.

[55]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[56]  N. Voelkel,et al.  The cancer paradigm of severe pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[57]  K. Jones,et al.  The multi-tasking P-TEFb complex. , 2008, Current opinion in cell biology.

[58]  Ludger Hengst,et al.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy , 2008, Nature Reviews Cancer.

[59]  Carlo Riccardi,et al.  Analysis of apoptosis by propidium iodide staining and flow cytometry , 2006, Nature Protocols.

[60]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[61]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[62]  I. Iakovidis,et al.  The road ahead. , 2004, Studies in health technology and informatics.

[63]  A. Giordano,et al.  CDK9: From Basal Transcription to Cancer and AIDS , 2002, Cancer biology & therapy.

[64]  J. Harral,et al.  p27Kip1 Is Important in Modulating Pulmonary Artery Smooth Muscle Cell Proliferation , 2001 .

[65]  Steven P. Angus,et al.  Retinoblastoma Tumor Suppressor Protein Signals through Inhibition of Cyclin-Dependent Kinase 2 Activity To Disrupt PCNA Function in S Phase , 2001, Molecular and Cellular Biology.

[66]  J. Harral,et al.  p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation. , 2001, American journal of respiratory cell and molecular biology.

[67]  E. Nabel,et al.  Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. , 2000, Circulation.

[68]  E. Nabel,et al.  Expression of cyclin-dependent kinase inhibitors in vascular disease. , 1998, Circulation research.